Gert Jan van der Hoeven
Founder and Managing Partner @ H2 Equity Partners
Amsterdam, The Netherlands
Gert Jan van der Hoeven is a Series A investor at H2 Equity Partners in Amsterdam focused on Health Care and Medical Device. Gert Jan has founded H2 in 1991 together with his long time friend Age Hollander. Gert Jan had graduated from his studies at the Delft University of Technology and the Rotterdam School of Management. After his graduations Gert Jan joined McKinsey & Company to work in The Netherlands, Germany and Switzerland. At McKinsey Gert Jan managed theworld wide company diagnostic approach.Gert Jan has built-up the H2 team and has introduced the firm's strong focus on operational value add, including several of the firm's approaches. He is Chairman of the Investment Committee of H2. Gert Jan's passion is to indeed build better companies. The areas of his knowledge include consumer goods (Lunch Garden), manufacturing (Eska Graphic Board and Meijn), wholesale and distribution (Smartwares).Gert Jan likes to spend time with his family.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Gert Jan van der Hoeven invests in
Stages Gert Jan van der Hoeven invests in
Countries Gert Jan van der Hoeven invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 1 (100%)
- Medical Device 1 (100%)
- Personalization 1 (100%)
- Quality Assurance 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
RTsafe
|
Founded in 2014, RTsafe is introducing Individualized Care to Radiation Oncology. It designs and manufactures the first FDA-cleared, patient-specific, anatomically-exact models of human head and brain tissue. These are offered to Radiotherapy clinics for simulating radiation therapy for each patient ahead of actual treatment in a totally risk-freeenvironment, thus maximizing cancer patient safety and treatment effectiveness during radiation therapy. This solution is also sold to RT equipment manufacturers for machine-testing purposes. After winning a R&D 100 Award, RTsafe’s PseudoPatientTM is recognized as one of the 100 most significant high-tech products worldwide for 2019. The company’s vision is a world where every radiotherapy intervention is tested on a PseudoPatient® before the real patient. | $2.3M / Series A / Mar 01, 2017 |
About H2 Equity Partners
H2 Equity Partners is a Western European hands-on investment firm with offices in Amsterdam and London.
H2 Equity Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Age Hollander
Founder
|
|||
Arjan Snijders
Investment Manager
|
|||
|
Gert Jan van der Hoeven
Founder and Managing Partner
|
|||
Harmen Geerts
Partner
|
|||
Patrick Kalverboer
Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Gert Jan van der Hoeven invest in?
Gert Jan van der Hoeven invests primarily in Health Care, Medical Device and Personalization startups, most often at Series A stage. Most of the 1 investments tracked by Shizune back companies in Greece. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Gert Jan van der Hoeven?
Public channels for Gert Jan van der Hoeven include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Gert Jan van der Hoeven last invest?
The most recent investment recorded for Gert Jan van der Hoeven closed in Mar 2017. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
